Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses

Yajie Lin, Jiajie Zhu, Zongming Liu, Chaonan Li, Yikai Guo, Ying Wang, Keda ChenFrontiers in Immunology 2022 · DOI

TL;DR

This review synthesizes current knowledge on how antibody levels change over time (kinetics) after SARS-CoV-2 infection and vaccination, and how these responses relate to disease severity and emerging variants. Understanding these dynamics is crucial for predicting immunity duration, informing public health strategies, and developing effective vaccines and therapeutics.

What Problem Does This Paper Address?

The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the critical role of the immune system in combating viral infections. While significant progress has been made in understanding the immune response to SARS-CoV-2, a key challenge remains: a comprehensive understanding of the kinetics of antibody responses. This refers to how antibody levels change over time after infection or vaccination, including their initial rise, peak, decline, and persistence. This knowledge gap is problematic because the duration and strength of antibody immunity directly influence future transmission, disease severity, and the effectiveness of vaccines and natural infection in providing protection. Furthermore, the emergence of SARS-CoV-2 variants of concern (VOCs) adds another layer of complexity, as these variants can potentially evade existing immunity. This review aims to consolidate existing research on antibody kinetics, their relationship with disease severity, and their effectiveness against VOCs, thereby addressing the need for a clearer picture of long-term immunity.

Methods

This paper is a review article, meaning it does not present new experimental data or novel methodologies. Instead, it synthesizes and analyzes existing research published in the scientific literature. The authors have systematically gathered and summarized findings from numerous studies focusing on:

  • Antibody kinetics: This involves analyzing data on the seroconversion time (when antibodies become detectable), peak antibody levels, and the rate and duration of antibody decline for different immunoglobulin classes (IgM, IgA, IgG) and neutralizing antibodies (Nabs).
  • Relationship with disease severity: The review examines how antibody responses differ between individuals with asymptomatic, mild, severe, or critical COVID-19.
  • Neutralizing antibody effectiveness against variants: The authors discuss studies evaluating the ability of antibodies generated by infection or vaccination to neutralize emerging SARS-CoV-2 variants of concern (VOCs).

The authors have organized this information by antibody isotype and by the type of immune stimulus (infection vs. vaccination), drawing upon a wide range of published studies, including longitudinal studies, cross-sectional analyses, and meta-analyses.

Datasets

Not discussed in the paper. As a review article, it synthesizes data from existing published studies rather than collecting or analyzing new datasets.

Key Insights and Ideas

  • Antibody dynamics are complex and isotype-dependent: Different antibody types (IgM, IgA, IgG) have distinct kinetics. IgM is an early responder but short-lived, IgA plays a role in mucosal immunity and can persist longer, while IgG is the most abundant and provides long-lasting immunity.
  • Severity influences antibody levels: Patients with severe or critical COVID-19 generally mount higher and more sustained antibody responses compared to those with mild or asymptomatic infections.
  • Neutralizing antibodies are key but wane: While neutralizing antibodies (Nabs) are crucial for preventing viral entry, their levels decline over time, often in a biphasic manner (rapid initial decline followed by a slower one).
  • Variants pose a significant challenge: Emerging VOCs, particularly Omicron, show increased resistance to neutralization by antibodies generated from prior infection or vaccination, highlighting the need for updated vaccines or boosters.
  • Vaccination and infection together offer robust protection: Combining natural infection with vaccination appears to induce a higher level of protection, potentially reaching a biological ceiling.
  • Cellular immunity remains vital: While the review focuses on antibodies, it acknowledges the indispensable role of T-cell responses, which are preserved against VOCs and crucial for controlling severe disease and long-term immunity.

Key Results

  • IgM: Typically detected around 7 days post-onset, peaks around 20 days, and declines significantly within months.
  • IgA: Appears early (5-8 days post-onset), with sIgA being important for mucosal defense. Its persistence can be longer than IgM, with some studies showing detectable levels for months.
  • IgG: Seroconversion occurs later (around 12 days post-onset), peaks around 25 days, and exhibits a more durable half-life compared to IgM and IgA, with some studies estimating half-lives of over 100 days for spike-specific IgG.
  • Neutralizing Antibodies (Nabs): Detected 6-15 days post-onset, peak around 14-45 days, and show a biphasic decay. While protective immunity can last for months to over a year, the ability to neutralize emerging variants is reduced.
  • Variant Neutralization: Omicron exhibits the strongest resistance to neutralization, followed by Beta, Delta, and Gamma. Alpha shows the weakest resistance among VOCs.
  • Vaccine Effectiveness: While vaccines induce robust neutralizing antibodies, effectiveness against variants like Omicron is reduced, especially after only two doses. Booster doses are shown to reverse this trend.

Limitations and Future Work

  • Heterogeneity in Studies: The authors note that differences in study methodologies, sample sizes, and detection techniques make direct comparisons across studies challenging.
  • Focus on Antibodies: The review primarily focuses on humoral immunity (antibodies) and acknowledges that cellular immunity (T cells) plays a crucial, complementary role that is not as extensively covered.
  • Long-Term Immunity: While significant progress has been made, the precise duration of protective immunity against severe disease and reinfection, especially in the context of evolving variants, remains an area requiring further investigation.
  • Future Directions: The authors emphasize the need for:
  • Developing more convenient and standardized methods for assessing cellular immune responses.
  • Establishing clearer correlations between antibody levels, cellular immunity, and actual immune protection (prevention of infection, severe disease, and critical symptoms).
  • Further research into the long-term waning of immune protection after infection and vaccination.
  • Personalized approaches to vaccination and booster timing, considering individual immune efficacy, vaccine availability, and circulating strains.

Summary updated

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world, causing severe morbidity and mortality. Since the first reports of Coronavirus disease 2019 (COVID-19) in late 2019, research on the characteristics of specific humoral immunity against SARS-CoV-2 in patients with COVID-19 has made great progress. However, our knowledge of persistent humoral immunity to SARS-CoV-2 infection is limited. The existence of protective immunity after infection will affect future transmission and disease severity. Therefore, it is important to gather knowledge about the kinetics of antibody responses. In this review, we summarize the information obtained so far on the characteristics and kinetics of the SARS-CoV-2 infection of specific humoral immune response, especially in neutralizing antibodies and their relationship with disease severity. In addition, with the emergence of variants of concern, we summarize the neutralizing effect of specific humoral immunity on variants of concern after the initial SARS-CoV-2 infection and vaccination.
BibTeX
@inproceedings{lin2022kinetics,
  author = {Yajie Lin and Jiajie Zhu and Zongming Liu and Chaonan Li and Yikai Guo and Ying Wang and Keda Chen},
  title = {{Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.864278},
}
Figure